Untapped potential of post-exposure prophylaxis in sub-Saharan Africa: a comparative analysis of PEP implementation planning in Kenya, Mozambique, Nigeria, Uganda and Zambia

Introduction

In 2023, over 210,000 new HIV acquisitions occurred in Kenya, Mozambique, Nigeria, Uganda and Zambia. While uptake of oral pre-exposure prophylaxis (oral PrEP) and coverage of voluntary medical male circumcision increased significantly over the past decade, post-exposure prophylaxis (PEP) has received less attention and remains an underused HIV prevention intervention. In 2024, the World Health Organization (WHO) released new guidance emphasizing the need for timely access to PEP, including through community-based channels and task-sharing to mitigate barriers such as stigma and ensure timely access. We conducted a comparative analysis of PEP implementation planning to understand how PEP is currently integrated into HIV prevention programmes, and to identify barriers and opportunities for optimizing the impact of PEP in the method mix.

Methods

We analysed Global Fund country proposals from Grant Cycle 6 (GC6) (2021−2023) and Grant Cycle 7 (GC7) (2024−2026) for five countries in Africa with high HIV burden and established PrEP programmes: Kenya, Mozambique, Nigeria, Uganda and Zambia. To understand how PEP implementation planning evolved across these two cycles, we used quantitative and qualitative analysis to identify trends. We extracted all PEP activities, coding them by focal population and activity type.

Results

We found over a five-fold increase in the number of PEP activities in GC7 compared to GC6, where there were only 10 PEP activities, and an expanded population focus, including people in prisons and pregnant and breastfeeding people. Proposals increasingly emphasized PEP not only as an intervention for occupational and sexual violence exposures but as a vital component of comprehensive HIV prevention strategies. Proposals described strategies for increasing access to PEP through differentiated service delivery models, including community-led and pharmacy-delivered approaches. However, PEP activities were not well defined, with PEP often included in product lists without articulating product-specific activities to address barriers or increase access.

Conclusions

All five countries demonstrated an increased focus on PEP from GC6 to GC7. While this reflects an ambition to expand access to PEP, product-specific activities were not clearly articulated. Practical guidance and tools, as well as focused cross-country learning to support the operationalization of WHO's recommendations, will be critical to increasing access and achieving impact.